GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Net Change in Cash

Soligenix (Soligenix) Net Change in Cash : $-3.17 Mil (TTM As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Soligenix Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Soligenix's Net Change in Cash for the three months ended in Mar. 2024 was $-1.35 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.17 Mil.

Soligenix Net Change in Cash Historical Data

The historical data trend for Soligenix's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Net Change in Cash Chart

Soligenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.56 13.26 7.37 -12.68 -4.91

Soligenix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.09 2.90 -2.86 -1.85 -1.35

Soligenix Net Change in Cash Calculation

Soligenix's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-8.604+0+3.664+0.027
=-4.91

Soligenix's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.342+0+-0.009+-0.003
=-1.35

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Soligenix Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Soligenix's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (Soligenix) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Net Change in Cash
Comparable Companies
SRNE CELZ HSTC TTNP KA BZYR ARTH HOTH SNPX XBIO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
0A6I:UK
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Website
https://www.soligenix.com
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
Timothy R. Cote director 3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube officer: CMO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber director, officer: Chairman, CEO and President 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino officer: Chief Financial Officer 100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini officer: CSO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson director, 10 percent owner 3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza other: Former 10% Owner VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144

Soligenix (Soligenix) Headlines

From GuruFocus

Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

By PRNewswire PRNewswire • 03-31-2023

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

By PRNewswire PRNewswire • 05-16-2023

Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures

By PRNewswire • 09-25-2023

Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

By ACCESSWIRE ACCESSWIRE • 06-02-2023

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Beh�et's Disease

By PRNewswire • 01-08-2024

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Beh�et's Disease

By PRNewswire PRNewswire • 05-01-2023

Soligenix Announces Reverse Stock Split

By PRNewswire PRNewswire • 02-09-2023

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte� New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

By PRNewswire PRNewswire • 02-14-2023

Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results

By PRNewswire • 08-21-2023

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte� in the Treatment of Cutaneous T-Cell Lymphoma

By PRNewswire PRNewswire • 05-11-2023